TRANSCRIPTIONAL CONTROL OF THE ERYTHROPOIETIN GENE
ONCOGENE SCIENCE, INC. · Department of Health and Human Services
Phase II1993$500,000
ERYTHROPOIETIN (EPO) INDUCES ERYTHROID PROGENITOR CELLS TO DIFFERENTIATE INTO ERYTHROCYTES. RECOMBINANT EPO IS APPROVED FOR TREATING ANEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE, AND IS BEING EVALUATED IN ANEMIAS ASSOC…